Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LU-TARGET: 177Lu-PSMA-617 for IDH Wild Type Gliomas
NCT07223034Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in glioma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Toxicity at 8 weeks. Started Oct 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07223034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223034.